Minnelide: a possible new drug for the treatment of CRPC?

According to a recently published article in The Prostate, researchers at the University of Minnesota have developed a new type of drug that they believe may have high therapeutic potential in the treatment of castration-resistant prostate cancer (CRPC). … READ MORE …

“Competitive analysis” in the development of drugs for advanced prostate cancer

So the other morning your sitemaster learned that a relatively new FirstWord Therapy Report had come out that dealt with future use of biopharmaceuticals in the treatment of progressive and advanced prostate cancer. … READ MORE …

The history of the clinical trials process

Readers with an interest in how we got to today’s clinical trials processes for evaluating new drugs for the treatment of prostate cancer and other diseases might be surprised by what’s in an article in this week’s New England Journal of Medicine. … READ MORE …

Effective, safe, and as fast as reasonably possible

For readers who are interested in the processes and the speed with which potential new cancer drugs can be brought to market here in the USA (and other places around the world too), there in an important article in this week’s New England Journal of Medicine. … READ MORE …

Of mice and men all over again …

Yet another set of researchers have found yet another possible new drug that seems to have significant activity in management of prostate cancer — in mice! Whether it will have activity in men is a whole other question. … READ MORE …

What’s a clonal neoantigen when it’s at home? And why is it important?

Many readers of this blog will be aware of the development of immunotherapies like sipuleucel-T (Provenge), CAR-T for the treatment of leukemias, and checkpoint inhibitors in the treatment of some forms of solid tumor (lung cancers, melanoma). … READ MORE …

Guessing the future price of the next major breakthrough in prostate cancer treatment

In an article published on Monday September 28, in Pharmaceutical Executive (a well-known biopharmaceutical industry trade journal) a senior health care public relations executive recently laid out a detailed rationale for why the industry needs to do a better job … READ MORE …